Mutation or high expression of FLT3 may cause the continuous activation of the protein, leading to acute myeloid leukemia and acute lymphocytic leukemia.167 There are currently eight drugs that can act on FLT3 have been approved, but these drugs have poor selectivity and can cause gastrointestinal intolerance, long-term cytopenias, hand-foot syndrome and other side effects.168 In addition, the single drug has limited efficacy in AML patients with FLT3 mutations. Here, FLT3 is linked to acute myeloid leukemia.